Search Result

Results for "

GSIS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (3) Apoptosis (3) Arrestin (1) Autophagy (1) Calcium Channel (1) DAPK (1) Endogenous Metabolite (7) Environmental Pollutants (1) Free Fatty Acid Receptor (3) GLP Receptor (1) Interleukin Related (1) IRAK (1) NF-κB (1) NKCC (1) Notch (4) Organoid (1) p38 MAPK (1) PROTACs (1) Reference Standards (3) TNF Receptor (1) γ-secretase (11)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (4) Metabolic Disease (10) Neurological Disease (10)
Oligonucleotides:	Preservatives (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13027

DAPT Maximum Cited Publications 158 Publications Verification GSI-IX	Organoid γ-secretase Amyloid-β Autophagy Notch Apoptosis	Neurological Disease Inflammation/Immunology Cancer
DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC₅₀s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ₄₂, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment .

HY-41417

Octanoic acid 3 Publications Verification Caprylic acid	Environmental Pollutants Endogenous Metabolite	Metabolic Disease
Octanoic acid (Caprylic acid) is an oily liquid with a slightly unpleasant rancid taste and used commercially in the production of esters used in perfumery and also in the manufacture of dyes. Octanoic acid is also a tremor-suppressing agent .

HY-175701

CT-996 RO7795081; RG6652	Arrestin GLP Receptor	Metabolic Disease
CT-996 is an orally active GLP-1RA agonist with an EC₅₀ of 0.49 nM. CT-996 reduces the recruitment of β-arrestin and the internalization of GLP-1R. CT-996 suppresses postprandial blood glucose in mice expressing human GLP-1 receptors and enhances glucose-stimulated insulin secretion (GSIS) in obese monkeys during intravenous glucose challenge. CT-996 can be used for the research of type 2 diabetes (T2D) and obesity .

HY-19369

L-685458 5+ Cited Publications L-685,458	γ-secretase Apoptosis	Neurological Disease Cancer
L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC₅₀ of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC₅₀s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers .

HY-13027G

DAPT GSI-IX	γ-secretase	Neurological Disease Inflammation/Immunology Cancer
DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active γ-secretase inhibitor .

HY-B1021

Vincamine 1 Publications Verification	Free Fatty Acid Receptor	Cardiovascular Disease Metabolic Disease
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-14175

Begacestat GSI-953	γ-secretase	Neurological Disease
Begacestat (GSI-953) is a selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase (IC₅₀Aβ₄₀=15 nM) for the treatment of Alzheimer's disease .

HY-N2319

Dihydroergocristine mesylate 1 Publications Verification DHEC mesylate	Amyloid-β	Neurological Disease
Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-18614

LY900009	Notch γ-secretase	Cancer
LY900009 is a potent and orally active, First-in-class inhibitor of Notch signaling via selective inhibition of the γ-secretase protein (GSI). LY900009 inhibits Notch signalling in tumor cell lines and endothelial cells (IC₅₀=0.005-20 nM). LY900009 can be used for advanced cancer research .

HY-14363

TUG-424	Free Fatty Acid Receptor	Metabolic Disease
TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity . TUG-424 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-158012

LY3056480	γ-secretase	Others
LY3056480 is a gamma-secretase inhibitor (GSI) that inhibits Notch signaling. LY3056480 improves mild to moderate sensorineural hearing loss and is safe and tolerable. Intratympanic administration of LY3056480 induces hair cell regeneration and partial hearing recovery in mammals .

HY-158584

13-OAHSA 9Z-Octadecenoic acid, 12-carboxy-1-pentyldodecyl ester	Endogenous Metabolite	Metabolic Disease
13-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-OAHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .

HY-158583

13-POHSA	Endogenous Metabolite	Metabolic Disease
13-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .

HY-158650

10-OAHSA	Endogenous Metabolite TNF Receptor	Inflammation/Immunology Endocrinology
10-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 10-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration. 10-OAHSA reduces LPS (HY-D1056)-induced Tnf-α secretion in bone marrow-derived dendritic cells (BMDCs) .

HY-Q40876

BBT	Calcium Channel	Metabolic Disease
BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ (HY-13753))-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway .

HY-164451

GSI-18	γ-secretase Notch	Cancer
GSI-18 is a γ-secretase inhibitor with anticancer activity. GSI-18 inhibits the attachment-free growth of pancreatic cancer cells by inhibiting Notch signaling .

HY-117236

GSI-136	γ-secretase	Neurological Disease
GSI-136 is an inhibitor of γ-secretase with an IC₅₀ of 3 nM. GSI-136 can lead to a dose-dependent reduction of Aβ40 levels in diethylamine-extracted brain homogenates of C57BL/6 mice. GSI-136 can be studied in medicinal chemistry and Alzheimer's disease research .

HY-115606

ML077	NKCC Endogenous Metabolite	Neurological Disease
ML007 is a selective antagonist targeting the neuron-specific potassium-chloride co-transporter 2 (KCC2) with an IC₅₀ for KCC2 is 537 nM, while its inhibitory activity on KCC1 is extremely weak (IC₅₀ > 50 μM). ML077 inhibits the chloride ion excretion function of KCC2, increasing the intracellular chloride ion concentration, thereby enhancing the depolarization mediated by chloride ion channels. ML007 can promote glucose-stimulated insulin secretion (GSIS) without relying on KATP channels. ML007 can be used to study the functions related to pain, epilepsy, and insulin secretion .

HY-178967

DRAK1/2-IN-2	DAPK Apoptosis Interleukin Related Endogenous Metabolite	Metabolic Disease
DRAK1/2-IN-2 (Compound Y17) is a DRAK1/2 inhibitor with IC₅₀ values for DRAK2 and DRAK1 of 353.2 nM and 507.4 nM respectively. DRAK1/2-IN-2 can enhance mitochondrial membrane potential and glucose-stimulated insulin secretion (GSIS). DRAK1/2-IN-2 resists lipotoxicity-induced cell apoptosis. DRAK1/2-IN-2 significantly inhibits the secretion of pro-inflammatory cytokine IL-1β, thereby exerting an anti-inflammatory effect. DRAK1/2-IN-2 can significantly lower the blood glucose levels of mice. DRAK1/2-IN-2 can be used in diabetes research.

HY-145428

BT-GSI	Notch γ-secretase	Cancer
BT-GSI is a γ-secretase inhibitor (GSI) and a bone-targeted Notch inhibitor. BT-GSI has dual anti-myeloma and anti-resorptive properties, which can be used for the research of multiple myeloma and associated bone disease. BT-GSI inhibits tumor growth and osteolytic disease progression .

HY-158639

12-POHSA	Endogenous Metabolite	Metabolic Disease
12-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 12-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .

HY-B1021R

Vincamine (Standard)	Reference Standards Free Fatty Acid Receptor	Cardiovascular Disease Metabolic Disease
Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-14175R

Begacestat (Standard) GSI-953 (Standard)	γ-secretase Reference Standards	Neurological Disease
Begacestat (Standard) is the analytical standard of Begacestat. This product is intended for research and analytical applications. Begacestat (GSI-953) is a selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase (IC50Aβ40=15 nM) for the treatment of Alzheimer's disease .

HY-N2319R

Dihydroergocristine mesylate (Standard) DHEC mesylate (Standard)	Reference Standards Amyloid-β	Neurological Disease
Dihydroergocristine (mesylate) (Standard) is the analytical standard of Dihydroergocristine (mesylate). This product is intended for research and analytical applications. Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-183799

GSI526	PROTACs IRAK NF-κB p38 MAPK	Inflammation/Immunology
GSI526 is a IRAK4 PROTAC degrader (DC₅₀=40.17 nM, D_max=97%; THP-1) based on the VHL ubiquitin-proteasome system. GSI526 inhibits IRAK4-mediated NF-κB and MAPK inflammatory signaling pathways, and induces IRAK4 degradation in myeloid cells. GSI526 is applicable to inflammation-related research .

HY-123761

L505-yne	γ-secretase	Neurological Disease
L505-yne is an active site-directed γ-secretase inhibitor. L505-yne blocks photoaffinity labeling of PS1-NTF, PS1-CTF, and SPP by clickable GSI photoprobes, binds the γ-secretase complex and inhibits Aβ42 production. L458-BPyne can be used for the research of Alzheimer’s disease .

DAPT GSI-IX	Fluorescent Dye
DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active γ-secretase inhibitor .

Cat. No.	Product Name	Type

HY-13027G

DAPT GSI-IX	Biochemical Assay Reagents
DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active γ-secretase inhibitor .

HY-158583

13-POHSA	Biochemical Assay Reagents
13-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-41417

Octanoic acid 3 Publications Verification Caprylic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Environmental Pollutants Endogenous Metabolite
Octanoic acid (Caprylic acid) is an oily liquid with a slightly unpleasant rancid taste and used commercially in the production of esters used in perfumery and also in the manufacture of dyes. Octanoic acid is also a tremor-suppressing agent .

HY-B1021

Vincamine 1 Publications Verification	Apocynaceae Cardiovascular Disease Alkaloids Classification of Application Fields Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	Free Fatty Acid Receptor
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-B1021R

Vincamine (Standard)	Apocynaceae Alkaloids Structural Classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	Reference Standards Free Fatty Acid Receptor
Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

Cat. No.	Product Name		Classification

HY-41417

Octanoic acid 3 Publications Verification Caprylic acid		Preservatives
Octanoic acid (Caprylic acid) is an oily liquid with a slightly unpleasant rancid taste and used commercially in the production of esters used in perfumery and also in the manufacture of dyes. Octanoic acid is also a tremor-suppressing agent .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13027G

DAPT GSI-IX	γ-secretase	Neurological Disease Inflammation/Immunology Cancer
DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active γ-secretase inhibitor .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

GSIS

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Oligonucleotides

GMP Molecules

Natural
Products